Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMID 25595139)

Published in Circulation on January 16, 2015

Authors

Kevin E Chan1, Elazer R Edelman2, Julia B Wenger2, Ravi I Thadhani2, Franklin W Maddux2

Author Affiliations

1: From Nephrology Division, Massachusetts General Hospital, Waltham, MA (K.E.C., J.B.W., R.I.T.); Clinical Research Division, Fresenius Medical Care North America, Waltham, MA (K.E.C., F.W.M.); Massachusetts Institute of Technology, Harvard-MIT Biomedical Engineering Center, Institute for Medical Engineering and Science, Cambridge, MA (E.R.E.); and Cardiovascular Medicine Division, Brigham and Women's Hospital, Boston, MA (E.R.E.). kevin.chan@fmc-na.com.
2: From Nephrology Division, Massachusetts General Hospital, Waltham, MA (K.E.C., J.B.W., R.I.T.); Clinical Research Division, Fresenius Medical Care North America, Waltham, MA (K.E.C., F.W.M.); Massachusetts Institute of Technology, Harvard-MIT Biomedical Engineering Center, Institute for Medical Engineering and Science, Cambridge, MA (E.R.E.); and Cardiovascular Medicine Division, Brigham and Women's Hospital, Boston, MA (E.R.E.).

Associated clinical trials:

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation (RENAL-AF) | NCT02942407

Articles citing this

Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con. Clin J Am Soc Nephrol (2016) 1.23

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors. J Am Soc Nephrol (2016) 0.91

Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues. J Stroke (2016) 0.85

Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Vasc Health Risk Manag (2015) 0.78

Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol (2016) 0.78

The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. Br J Clin Pharmacol (2016) 0.77

Reply: Warfarin in patients on haemodialysis with atrial fibrillation—friend or foe? Nat Rev Nephrol (2015) 0.75

Anticoagulation in Atrial Fibrillation - Current Concepts. Arrhythm Electrophysiol Rev (2015) 0.75

Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart (2016) 0.75

Use of Oral Anticoagulation for Patients with ESRD on Hemodialysis with Atrial Fibrillation: Verdict 1. Clin J Am Soc Nephrol (2016) 0.75

Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis. Thromb Res (2016) 0.75

Emerging Tools for Stroke Prevention in Atrial Fibrillation. EBioMedicine (2016) 0.75

Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol (2017) 0.75

Cardiovascular Pharmacogenomics-Implications for Patients With CKD. Adv Chronic Kidney Dis (2016) 0.75

Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Intern Emerg Med (2017) 0.75

Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry. Heart Vessels (2016) 0.75

Articles cited by this

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98

Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med (1998) 3.44

Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40

Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.55

National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes (2012) 2.27

Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost (2013) 1.83

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2010) 1.71

Can we rely on RE-LY? N Engl J Med (2009) 1.58

Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem (2002) 1.51

New options in anticoagulation for atrial fibrillation. N Engl J Med (2011) 0.97

Dabigatran and kidney disease: a bad combination. Clin J Am Soc Nephrol (2013) 0.95

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 0.81